Peptide Information Hub
Peptide Information Hub
Research library.
Educational resource.
A growing reference library covering commonly researched compounds, their scientific backgrounds, and the current state of evidence. Built for curious, informed readers. All claims sourced and linked.
⚠ Important Notice — Please Read
This page is intended strictly for educational and informational purposes. All content is presented as general scientific awareness and does not constitute medical advice, treatment recommendations, or endorsement of any compound for human use.
Under Health Canada's Food and Drugs Act, most synthetic injectable peptides are classified as prescription drugs. Unauthorized sale or use of these compounds for human consumption is illegal in Canada. The compounds discussed on this page are referenced in the context of scientific research and general educational awareness only. Stratik Performance Labs sells storage and organization accessories — we do not sell, supply, or distribute peptide compounds of any kind.
Always consult a licensed healthcare professional before making any health-related decisions. Research-use compounds should only be handled by qualified researchers in appropriate settings.
Why we built this resource
The peptide research space is growing rapidly — and so is the amount of misinformation surrounding it. Too many resources either overstate unproven benefits or provide no scientific context at all. We built this library to sit in the middle: accurate, sourced, honest about what the evidence actually says, and clear about where research gaps exist.
Each compound entry includes a category classification, a plain-language overview, current research context, an evidence level indicator, and direct links to primary sources so you can read further yourself.
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed for type 2 diabetes management. It mimics the body's natural GLP-1 hormone, which regulates insulin secretion, slows gastric emptying, and signals satiety to the brain. Sold under brand names Ozempic, Wegovy, and Rybelsus.
Current research context
The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events in overweight adults with established heart disease, leading to FDA approval for cardiovascular risk reduction in March 2024. Health Canada subsequently approved Ozempic for cardiovascular risk reduction in March 2026. Strong randomized controlled trial data underpins all approved indications.
Tirzepatide targets both GLP-1 and GIP receptors simultaneously. Approved under brand names Mounjaro (diabetes, 2022) and Zepbound (weight management, 2023). In December 2024 it received additional FDA approval for moderate-to-severe obstructive sleep apnea in adults with obesity.
Current research context
The SURMOUNT-5 head-to-head trial found approximately 20.2% average weight loss with tirzepatide versus 13.7% with semaglutide over 72 weeks. By Q3 2025, tirzepatide became the world's best-selling drug with $10.1 billion in a single quarter.
Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, building on tirzepatide's dual-agonist approach with a third mechanism. Currently in Phase 3 clinical trials as of 2025–2026. Not approved for any use.
Current research context
Early phase results generated significant interest in obesity medicine research communities. Researchers have flagged that gray-market marketing of Retatrutide has significantly outpaced verified clinical data — a pattern well-documented in the research peptide space.
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH), comprising the full 44-amino-acid sequence of human GRF. Manufactured by Theratechnologies Inc., a Montreal-based Canadian company. It stimulates the pituitary gland to produce and release growth hormone through the body's natural physiological pathway.
Current research context
FDA-approved in 2010 and Health Canada-approved under the brand name Egrifta for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. One of the few growth hormone-related peptides with a full regulatory approval pathway in both Canada and the US.
AOD-9604 is a synthetic fragment of human growth hormone (amino acids 176–191), originally investigated for potential metabolic effects without growth-promoting properties. Developed by Monash University in Australia. Failed to meet primary endpoints in Phase 3 clinical trials for obesity treatment.
Current research context
Not approved by Health Canada or the FDA for any indication. Currently discussed within research and fitness communities. Expected to return to US legal compounding status following the February 2026 HHS announcement.
BPC-157 is a synthetic 15-amino-acid peptide derived from a naturally occurring protein found in gastric juice. It has been the subject of extensive preclinical research over three decades, generating scientific interest in tissue repair, angiogenesis, and gastrointestinal health. Also on the World Anti-Doping Agency (WADA) Prohibited List.
Current research context
A 2025 systematic review screened 544 papers — 35 of 36 meeting inclusion criteria were rodent or cell-based, with only one involving humans in a musculoskeletal context. The FDA classified it Category 2 for compounding in 2023 citing insufficient human safety data. Health Canada has issued specific warnings naming BPC-157. A randomized, double-blind, placebo-controlled human trial has been registered. Expected to return to US compounding status following the February 2026 HHS announcement.
TB-500 is a synthetic fragment derived from thymosin beta-4 (Tβ4), an endogenous protein naturally upregulated in response to tissue injury. The active peptide segment promotes actin polymerization, progenitor cell recruitment, and enhanced cellular migration — processes central to wound healing and tissue repair.
Current research context
Preclinical studies and veterinary applications have suggested benefit in tendon and muscle repair, with observed anti-inflammatory and proangiogenic activity. A 2025 peer-reviewed orthopaedics review noted TB-500 alongside BPC-157 and GHK-Cu as compounds of interest for tissue repair. Health Canada has specifically named TB-500 in its advisory warnings. No approved human indication exists.
GHK-Cu is a naturally occurring tripeptide (glycine-histidine-lysine) that binds copper and plays a role in skin and connective tissue remodeling. Uniquely positioned among research peptides as it has an established legitimate use pathway in cosmetics, distinguishing it from most research compounds.
Current research context
Research has documented GHK-Cu's role in stimulating dermal fibroblast proliferation, regulating matrix metalloproteinases, and supporting collagen turnover. A 2025 peer-reviewed orthopaedics review noted its research relevance in connective tissue contexts. Topical cosmetic use is fully within regulatory norms in both Canada and the US.
KPV (Lysine-Proline-Valine) is a tripeptide fragment derived from the C-terminal end of alpha-melanocyte-stimulating hormone (α-MSH). Studied primarily for potential anti-inflammatory properties in gastrointestinal and dermatological research contexts.
Current research context
Research has focused on KPV's potential to modulate inflammatory pathways, with preclinical studies examining its role in gut health and inflammatory bowel conditions. Evidence remains early-stage and predominantly preclinical. Among the compounds expected to return to US legal compounding status following the February 2026 HHS announcement. Not approved by Health Canada.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) engineered with an extended half-life via Drug Affinity Complex (DAC) technology. It stimulates the pituitary gland to release growth hormone and has been researched in academic and laboratory contexts.
Current research context
Health Canada has specifically named CJC-1295 in its advisory warning Canadians against purchasing unauthorized injectable peptides online. Canadian laboratories have contributed research on CJC-1295 to the global scientific literature. Among the compounds expected to return to US legal compounding status following the February 2026 HHS announcement. No approved human indication exists in Canada or the US.
Ipamorelin is a selective growth hormone secretagogue and member of the GHRP family. Its selectivity for growth hormone release — with minimal effect on cortisol and prolactin — has made it a compound of research interest. Frequently studied in combination with CJC-1295.
Current research context
Health Canada has specifically named Ipamorelin in its advisory warning against unauthorized injectable peptides. Human clinical trial data is limited relative to the volume of community discussion. No approved human indication in Canada or the US.
MK-677 (Ibutamoren) is a non-peptide growth hormone secretagogue that mimics the action of ghrelin, stimulating GH and IGF-1 release. Often discussed alongside peptides due to similar mechanisms. Oral bioavailability distinguishes it from most injectable research compounds.
Current research context
Has been studied in clinical trials for conditions including growth hormone deficiency and muscle wasting. Despite years of investigation, it has not progressed to regulatory approval. Carries regulatory risk in Canada as an unauthorized health product when marketed for human use.
Semax is a synthetic heptapeptide analogue of adrenocorticotropic hormone (ACTH), developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It has garnered attention in western nootropic communities for potential effects on cognitive function and neuroprotection.
Current research context
Approved as a drug in Russia for stroke recovery and cognitive impairment. Not approved in Canada or the US. Among the compounds expected to return to US legal compounding status following the February 2026 HHS announcement. Western peer-reviewed evidence remains limited compared to Russian clinical literature.
Selank is a synthetic heptapeptide analogue of tuftsin, developed alongside Semax at the Institute of Molecular Genetics in Russia. Investigated primarily for anxiolytic and cognitive-enhancing properties without the sedative effects associated with traditional anxiolytics.
Current research context
Approved for clinical use in Russia. Research suggests modulation of GABA and serotonin systems. Among the compounds expected to return to US legal compounding status following the February 2026 HHS announcement. Not approved in Canada or the US.
Epitalon is a synthetic tetrapeptide based on Epithalamin, extracted from the pineal gland. Originally developed at the St. Petersburg Institute of Bioregulation and Gerontology. Research interest has focused on potential effects on telomerase activity — the enzyme associated with telomere length maintenance.
Current research context
Research conducted primarily by Russian scientists suggests effects on telomerase activity and aging-related biomarkers in animal models. Robust peer-reviewed human trial data from western institutions is limited. Not approved anywhere as a drug. Interest remains high given the scientific plausibility of the telomerase mechanism.
MOTS-c is a peptide encoded within mitochondrial DNA, first described in a 2015 Cell Metabolism paper. It challenged the long-held view that mitochondria only produce energy, revealing they also produce bioactive signalling peptides. A subject of significant scientific interest in longevity and metabolic research.
Current research context
Research has focused on MOTS-c's potential role in metabolic regulation, insulin sensitivity, and cellular stress responses. Circulating MOTS-c levels appear to decline with age, suggesting a potential role in age-related metabolic changes. Evidence is early-stage and primarily from animal studies.
Melanotan II is a synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH), originally investigated as a potential tanning agent by researchers at the University of Arizona. Activates multiple melanocortin receptors.
Current research context
Not approved by Health Canada, the FDA, or any major regulatory body. Health agencies in multiple countries have issued warnings due to a significant adverse effect profile observed in users. Not among the compounds expected to return to US compounding status. Included here for educational awareness only.
PT-141 (Bremelanotide) is a synthetic melanocortin receptor agonist originally derived from Melanotan II research. Unlike Melanotan II, PT-141 took a focused clinical pathway, resulting in regulatory approval in the US — a notable example of a research-community compound successfully completing the full clinical trial and approval process.
Current research context
Approved by the FDA in June 2019 under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. Not currently approved by Health Canada. Illustrates how a compound can progress from research interest to clinical approval with adequate human trial investment.
DSIP (Delta Sleep-Inducing Peptide) is an endogenous neuropeptide first isolated in 1974 from the cerebral venous blood of sleeping rabbits by Swiss researchers. Studied for potential roles in sleep regulation, stress modulation, and biological rhythm research.
Current research context
Despite decades of research, DSIP's exact mechanism of action and physiological role remain incompletely understood. Studies have been inconsistent with results varying significantly across methodologies. Not approved for any indication by Health Canada or the FDA.
Proper storage matters in peptide research
Peptide compounds are sensitive molecules. Temperature stability, light exposure, and moisture all affect compound integrity. Proper storage infrastructure is a foundational requirement for any research context.
Lyophilized (dry) peptides
Generally stable at room temperature short-term. Refrigeration (2–8°C) recommended for longer storage. Freezing for extended periods.
Reconstituted peptides
Once reconstituted in solution, refrigeration is typically required. Solutions degrade faster than lyophilized forms.
Light & moisture
Most peptides are sensitive to UV light and humidity. Opaque, sealed containers in controlled environments are standard practice.
Temperature control
Consistent temperature is critical. Freeze-thaw cycles can degrade peptide structure. Dedicated refrigeration supports consistent research environments.
Need the right storage system?
Stratik's storage and organization products are designed to support clean, structured, temperature-controlled research environments.
Browse the catalog →